This company has been acquired
DICE Stock Overview
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
DICE Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.55 |
| 52 Week High | US$47.90 |
| 52 Week Low | US$15.08 |
| Beta | 0 |
| 1 Month Change | 1.67% |
| 3 Month Change | 32.90% |
| 1 Year Change | 131.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 28.90% |
Recent News & Updates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Shareholder Returns
| DICE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.2% | -3.8% | 3.9% |
| 1Y | 131.2% | -7.4% | 11.6% |
Return vs Industry: DICE exceeded the US Pharmaceuticals industry which returned 7.3% over the past year.
Return vs Market: DICE exceeded the US Market which returned 4.8% over the past year.
Price Volatility
| DICE volatility | |
|---|---|
| DICE Average Weekly Movement | 11.3% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: DICE's share price has been volatile over the past 3 months.
Volatility Over Time: DICE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 81 | J. Judice | www.dicetherapeutics.com |
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications.
DICE Therapeutics, Inc. Fundamentals Summary
| DICE fundamental statistics | |
|---|---|
| Market cap | US$2.27b |
| Earnings (TTM) | -US$104.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.8x
P/E RatioIs DICE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DICE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$62.56m |
| Gross Profit | -US$62.56m |
| Other Expenses | US$41.68m |
| Earnings | -US$104.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DICE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/10 11:52 |
| End of Day Share Price | 2023/08/08 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DICE Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |